Advertisement
Screener

MACROGENICS, INC. (MGNX) Increase (Decrease) in Deferred Revenue

2.8 / 5 stars · 68/120 Roast Me

MACROGENICS, INC. Increase (Decrease) in Deferred Revenue

MACROGENICS, INC. (MGNX) reported Increase (Decrease) in Deferred Revenue of $13.40 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-26.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2019-02-26

  • MACROGENICS, INC. increase (decrease) in deferred revenue for the quarter ending 2018-12-31 was $19.21M, a 108.85% increase year-over-year.
  • MACROGENICS, INC. increase (decrease) in deferred revenue for the quarter ending 2018-09-30 was -$2.44M.
  • MACROGENICS, INC. increase (decrease) in deferred revenue for the quarter ending 2018-06-30 was -$1.94M.
  • MACROGENICS, INC. increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was -$1.44M.
  • MACROGENICS, INC. increase (decrease) in deferred revenue for fiscal 2018 was $13.40M, a 105.19% increase from fiscal 2017.
  • MACROGENICS, INC. increase (decrease) in deferred revenue for fiscal 2017 was $6.53M.
  • MACROGENICS, INC. increase (decrease) in deferred revenue for fiscal 2016 was -$4.19M.
  • MACROGENICS, INC. increase (decrease) in deferred revenue for fiscal 2015 was -$12.22M, a 468.50% decline from fiscal 2014.
Period endIncrease (Decrease) in Deferred Revenue 3 monthIncrease (Decrease) in Deferred Revenue 3 month as first filedIncrease (Decrease) in Deferred Revenue 6 monthIncrease (Decrease) in Deferred Revenue 9 monthIncrease (Decrease) in Deferred Revenue 9 month as first filedIncrease (Decrease) in Deferred Revenue 12 monthIncrease (Decrease) in Deferred Revenue 12 month as first filed
2018-12-31$19.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26
$16.78M
derived: sum of 2 quarters · filed 2019-02-26
$14.84M
derived: sum of 3 quarters · filed 2019-02-26
$13.40M
10-K · filed 2019-02-26
2018-09-30-$2.44M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
-$4.37M
derived: sum of 2 quarters · filed 2018-11-07
-$5.81M
10-Q · filed 2018-11-07
$3.39M
derived: sum of 4 quarters · filed 2019-02-26
2018-06-30-$1.94M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07
-$3.37M
10-Q · filed 2018-08-07
$5.83M
derived: sum of 3 quarters · filed 2019-02-26
$5.03M
derived: sum of 4 quarters · filed 2019-02-26
2018-03-31-$1.44M
10-Q · filed 2018-05-07
$7.76M
derived: sum of 2 quarters · filed 2019-02-26
$6.96M
derived: sum of 3 quarters · filed 2019-02-26
$6.16M
derived: sum of 4 quarters · filed 2019-02-26
2017-12-31$9.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26
$8.40M
derived: sum of 2 quarters · filed 2019-02-26
$7.60M
derived: sum of 3 quarters · filed 2019-02-26
$6.53M
10-K · filed 2019-02-26
2017-09-30-$800.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
-$1.60M
derived: sum of 2 quarters · filed 2018-11-07
-$2.67M
10-Q · filed 2018-11-07
-$1.94M
derived: sum of 4 quarters · filed 2019-02-26
2017-06-30-$801.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07
-$1.87M
10-Q · filed 2018-08-07
-$1.14M
derived: sum of 3 quarters · filed 2019-02-26
-$2.88M
derived: sum of 4 quarters · filed 2019-02-26
2017-03-31-$1.06M
10-Q · filed 2018-05-07
-$336.00K
derived: sum of 2 quarters · filed 2019-02-26
-$2.08M
derived: sum of 3 quarters · filed 2019-02-26
-$3.36M
derived: sum of 4 quarters · filed 2019-02-26
2016-12-31$729.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26
-$1.01M
derived: sum of 2 quarters · filed 2019-02-26
-$2.30M
derived: sum of 3 quarters · filed 2019-02-26
-$4.19M
10-K · filed 2019-02-26
2016-09-30-$1.74M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08
-$3.03M
derived: sum of 2 quarters · filed 2017-11-08
-$4.92M
10-Q · filed 2017-11-08
-$5.47M
derived: sum of 4 quarters · filed 2018-02-27
2016-06-30-$1.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02
-$3.18M
10-Q · filed 2017-08-02
-$3.73M
derived: sum of 3 quarters · filed 2018-02-27
-$7.59M
derived: sum of 4 quarters · filed 2018-02-27
2016-03-31-$1.89M
10-Q · filed 2017-05-03
-$2.45M
derived: sum of 2 quarters · filed 2018-02-27
-$6.30M
derived: sum of 3 quarters · filed 2018-02-27
-$10.17M
derived: sum of 4 quarters · filed 2018-02-27
2015-12-31-$555.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
-$4.41M
derived: sum of 2 quarters · filed 2018-02-27
-$8.27M
derived: sum of 3 quarters · filed 2018-02-27
-$12.22M
10-K · filed 2018-02-27
2015-09-30-$3.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02
-$7.72M
derived: sum of 2 quarters · filed 2016-11-02
-$11.67M
10-Q · filed 2016-11-02
-$15.62M
derived: sum of 4 quarters · filed 2017-02-28
2015-06-30-$3.86M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03
-$7.81M
10-Q · filed 2016-08-03
-$11.76M
derived: sum of 3 quarters · filed 2017-02-28
-$21.69M
derived: sum of 4 quarters · filed 2017-02-28
2015-03-31-$3.95M
10-Q · filed 2016-05-04
-$7.90M
derived: sum of 2 quarters · filed 2017-02-28
-$17.82M
derived: sum of 3 quarters · filed 2017-02-28
-$10.05M
derived: sum of 4 quarters · filed 2017-02-28
2014-12-31-$3.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28
-$13.88M
derived: sum of 2 quarters · filed 2017-02-28
-$6.11M
derived: sum of 3 quarters · filed 2017-02-28
$3.32M
10-K · filed 2017-02-28
2014-09-30-$9.93M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04
-$2.16M
derived: sum of 2 quarters · filed 2015-11-04
$7.27M
10-Q · filed 2015-11-04
$4.56M
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30$7.77M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05
$17.19M
10-Q · filed 2015-08-05
$14.49M
derived: sum of 3 quarters · filed 2016-02-29
$7.29M
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31$9.42M
10-Q · filed 2015-05-06
$9.42M
10-Q · filed 2014-05-06
$6.72M
derived: sum of 2 quarters · filed 2016-02-29
-$481.00K
derived: sum of 3 quarters · filed 2016-02-29
-$7.59M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31-$2.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
-$9.90M
derived: sum of 2 quarters · filed 2016-02-29
-$17.01M
derived: sum of 3 quarters · filed 2016-02-29
-$16.68M
10-K · filed 2016-02-29
-$16.68M
10-K · filed 2014-03-20
2013-09-30-$7.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12
-$14.31M
derived: sum of 2 quarters · filed 2014-11-12
-$13.97M
10-Q · filed 2014-11-12
-$13.97M
10-Q · filed 2013-11-12
$3.16M
derived: sum of 4 quarters · filed 2015-03-03
2013-06-30-$7.11M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05
-$6.77M
10-Q · filed 2014-08-05
$10.35M
derived: sum of 3 quarters · filed 2015-03-03
2013-03-31$339.00K
10-Q · filed 2014-05-06
$17.46M
derived: sum of 2 quarters · filed 2015-03-03
2012-12-31$17.13M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03
-$10.81M
10-K · filed 2015-03-03
-$10.81M
10-K · filed 2014-03-20
2012-09-30-$27.94M
10-Q · filed 2013-11-12
2011-12-31-$4.28M
10-K · filed 2014-03-20

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35